This study tests the safety and effects of a new drug called KAN-101 for people with Celiac Disease, a condition where eating gluten causes harm to the small intestine. The study is in three parts and includes up to 132 adult participants. Part A tests different amounts of KAN-101 to see how safe it is. Parts B and C compare KAN-101 with a placebo (a pill with no medicine) to see how the body responds. Participants must be on a gluten-free diet and will face a gluten challenge test to check the body's reaction. The study lasts about 56 days, with 28 days for checking if you can join, 7 days of taking the drug, and 21 days of follow-up.

• Duration: 56 days total, including screening, treatment, and follow-up.
• Eligibility: Adults with Celiac Disease on a gluten-free diet.
• Risks: Gluten challenge test may cause symptoms.

You can participate if you have Celiac Disease, follow a gluten-free diet for at least a year, and meet certain genetic and health conditions. You cannot join if you have other illnesses like diabetes or have had a gluten challenge recently. Always discuss with your doctor before joining a study.